Target Name: RBBP5
NCBI ID: G5929
Review Report on RBBP5 Target / Biomarker Content of Review Report on RBBP5 Target / Biomarker
RBBP5
Other Name(s): Retinoblastoma-binding protein RBQ-3 | RB binding protein 5, histone lysine methyltransferase complex subunit, transcript variant 2 | RBBP5 variant 1 | RBBP5_HUMAN | Retinoblastoma-binding protein 5 | RB binding protein 5, histone lysine methyltransferase complex subunit | RB binding protein 5, histone lysine methyltransferase complex subunit, transcript variant 1 | retinoblastoma-binding protein 5 | Retinoblastoma-binding protein 5 (isoform 1) | retinoblastoma-binding protein RBQ-3 | RBBP5 variant 2 | Retinoblastoma-binding protein 5 (isoform 2) | SWD1 | RBBP-5 | RBQ3 | SWD1, Set1c WD40 repeat protein, homolog | Retinoblastoma binding protein 5

RBBP 5: A Potential Drug Target Or Biomarker

Retinoblastoma-binding protein (RBBP) 5 is a protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is also known as RBQ-3 and has been identified as a potential drug target or biomarker for various diseases, including cancer.

The RBBP gene was first identified in 2003 and has since been shown to encode a protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. The protein has been shown to localize to the endoplasmic reticulum and to interact with various proteins, including the protein known as retinoblastoma-binding protein (RBBP) 1.

RBBP 5 has been shown to play a role in several biological processes, including cell signaling, DNA replication, and cell survival. It has also been shown to be involved in the development and progression of various diseases, including cancer.

One of the most promising aspects of RBBP 5 is its potential as a drug target or biomarker. Several studies have shown that inhibiting RBBP 5 can lead to a variety of therapeutic effects, including the inhibition of cancer cell growth, the inhibition of neurodegenerative diseases, and the improvement of insulin sensitivity.

In addition to its potential therapeutic uses, RBBP 5 has also been shown to be a potential biomarker for several diseases. For example, it has been shown to be a useful biomarker for the diagnosis of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to be a useful biomarker for the diagnosis of cancer, including pancreatic and ovarian cancers.

Overall, RBBP 5 is a protein that has significant potential as a drug target or biomarker. Further research is needed to fully understand its role in these biological processes and to develop effective therapies based on it.

Protein Name: RB Binding Protein 5, Histone Lysine Methyltransferase Complex Subunit

Functions: In embryonic stem (ES) cells, plays a crucial role in the differentiation potential, particularly along the neural lineage, regulating gene induction and H3 'Lys-4' methylation at key developmental loci, including that mediated by retinoic acid (By similarity). Does not affect ES cell self-renewal (By similarity). Component or associated component of some histone methyltransferase complexes which regulates transcription through recruitment of those complexes to gene promoters (PubMed:19131338). As part of the MLL1/MLL complex, involved in mono-, di- and trimethylation at 'Lys-4' of histone H3 (PubMed:19556245). Histone H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation (PubMed:19556245). In association with ASH2L and WDR5, stimulates the histone methyltransferase activities of KMT2A, KMT2B, KMT2C, KMT2D, SETD1A and SETD1B (PubMed:22266653, PubMed:21220120)

The "RBBP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBBP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2